Wei-Chiang Shen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11262255/publications.pdf

Version: 2024-02-01

69 papers	4,283 citations	147801 31 h-index	114465 63 g-index
70 all docs	70 docs citations	70 times ranked	5531 citing authors

#	Article	IF	Citations
1	Fusion protein linkers: Property, design and functionality. Advanced Drug Delivery Reviews, 2013, 65, 1357-1369.	13.7	1,273
2	Cell Penetrating Peptides: Intracellular Pathways and Pharmaceutical Perspectives. Pharmaceutical Research, 2007, 24, 1977-1992.	3.5	398
3	Cis-aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochemical and Biophysical Research Communications, 1981, 102, 1048-1054.	2.1	267
4	Insertion of the Designed Helical Linker Led to Increased Expression of Tf-Based Fusion Proteins. Pharmaceutical Research, 2009, 26, 523-528.	3.5	121
5	Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7292-7296.	7.1	117
6	Reversible lipidization for the oral delivery of salmon calcitonin. Journal of Controlled Release, 2003, 88, 369-380.	9.9	114
7	Improving the Oral Efficacy of Recombinant Granulocyte Colony-Stimulating Factor and Transferrin Fusion Protein by Spacer Optimization. Pharmaceutical Research, 2006, 23, 2116-2121.	3.5	108
8	Human growth hormoneâ€“transferrin fusion protein for oral delivery in hypophysectomized rats. Journal of Controlled Release, 2010, 141, 177-182.	9.9	87
9	Transcellular Delivery of an Insulin-Transferrin Conjugate in Enterocyte-like Caco-2 Cells. Journal of Pharmaceutical Sciences, 1996, 85, 1306-1311.	3.3	82
10	Oral peptide and protein delivery: unfulfilled promises?. Drug Discovery Today, 2003, 8, 607-608.	6.4	81
11	Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochemical and Biophysical Research Communications, 2003, 307, 241-247.	2.1	78
12	Acid-sensitive hybrid polymeric micelles containing a reversibly activatable cell-penetrating peptide for tumor-specific cytoplasm targeting. Journal of Controlled Release, 2018, 279, 147-156.	9.9	61
13	The cellular uptake of horseradish peroxidase and its poly(lysine) conjugate by cultured fibroblasts is qualitatively similar despite a 900-fold difference in rate. Journal of Cellular Physiology, 1982, 113, 167-178.	4.1	59
14	Conjugation of methotrexate to poly (L-lysine) as a potential way to overcome drug resistance. Cancer, 1980, 45, 1207-1211.	4.1	55
15	Design of an in vivo cleavable disulfide linker in recombinant fusion proteins. BioTechniques, 2010, 49, 513-518.	1.8	55
16	Conjugation with Cationic Cell-Penetrating Peptide Increases Pulmonary Absorption of Insulin. Molecular Pharmaceutics, 2009, 6, 492-503.	4.6	52
17	(C) Means to enhance penetration. Advanced Drug Delivery Reviews, 1992, 8, 93-113.	13.7	51
18	Nuclear Localization of Cell-Penetrating Peptides Is Dependent on Endocytosis Rather Than Cytosolic Delivery in CHO Cells. Molecular Pharmaceutics, 2009, 6, 337-344.	4.6	51

#	Article	IF	Citations
19	Reversible lipidization for the oral delivery of leu-enkephalin. Journal of Drug Targeting, 2006, 14, 127-136.	4.4	49
20	Evidence that membrane transduction of oligoarginine does not require vesicle formation. Experimental Cell Research, 2005, 307, 164-173.	2.6	47
21	Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells. Molecular Pharmaceutics, 2016, 13, 262-271.	4.6	47
22	Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates. Pharmaceutical Research, 2002, 19, 609-614.	3.5	46
23	Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity. Pharmaceutical Research, 1999, 16, 1674-1679.	3.5	44
24	Transcytosis of GCSF-transferrin across rat alveolar epithelial cell monolayers. Pharmaceutical Research, 2003, 20, 1231-1238.	3.5	44
25	Fatty acids as therapeutic auxiliaries for oral and parenteral formulations. Advanced Drug Delivery Reviews, 2013, 65, 1331-1339.	13.7	43
26	Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide. Biomaterials, 2014, 35, 4082-4087.	11.4	42
27	Cationic and amphipathic cell-penetrating peptides (CPPs): Their structures and in vivo studies in drug delivery. Frontiers of Chemical Science and Engineering, 2015, 9, 407-427.	4.4	40
28	Comparison of monomeric and oligomeric transferrin as potential carrier in oral delivery of protein drugs. Journal of Controlled Release, 2005, 106, 273-286.	9.9	38
29	Reversible Lipidization Prolongs the Pharmacological Effect, Plasma Duration, and Liver Retention of Octreotide. Pharmaceutical Research, 2005, 22, 220-227.	3.5	37
30	Interaction between Cell-Penetrating Peptides and Acid-Sensitive Anionic Oligopeptides as a Model for the Design of Targeted Drug Carriers. Molecular Pharmaceutics, 2014, 11, 1583-1590.	4.6	37
31	Membrane Transduction of Oligoarginine in HeLa Cells Is Not Mediated by Macropinocytosis. Molecular Pharmaceutics, 2006, 3, 181-186.	4.6	33
32	The Establishment of Polarity and Enhanced Transcytosis of Transferrin Receptors in Enterocyte-like Caco-2 Cells. Journal of Drug Targeting, 1994, 2, 93-99.	4.4	32
33	Tyrphostin-8 enhances transferrin receptor-mediated transcytosis in Caco-2- cells and inreases hypoglycemic effect of orally administered insulin-transferrin conjugate in diabetic rats. , 2001, 18, 191-195.		31
34	Effects of Receptor Binding on Plasma Half-Life of Bifunctional Transferrin Fusion Proteins. Molecular Pharmaceutics, 2011, 8, 457-465.	4.6	31
35	Discovery of an Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B. International Journal of Molecular Sciences, 2020, 21, 21.	4.1	31
36	Recombinant peptide constructs for targeted cell penetrating peptide-mediated delivery. Journal of Controlled Release, 2012, 158, 357-361.	9.9	30

#	Article	IF	Citations
37	Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 581-595.	3.3	28
38	Carbamylation Decreases the Cytotoxicity but not the Drug-Carrier Properties of Polylysines. Journal of Drug Targeting, 1995, 2, 469-475.	4.4	25
39	Lipidization of human interferon-alpha: A new approach toward improving the delivery of protein drugs. Journal of Controlled Release, 2008, 129, 11-17.	9.9	24
40	The influence of net charge and charge distribution on cellular uptake and cytosolic localization of arginine-rich peptides. Journal of Drug Targeting, 2011, 19, 675-680.	4.4	24
41	Characterization of transferrin receptor-mediated endocytosis and cellular iron delivery of recombinant human serum transferrin from rice (Oryza sativaL.). BMC Biotechnology, 2012, 12, 92.	3.3	23
42	Gastric retention and stability of lipidized Bowmanâ€“Birk protease inhibitor in mice. International Journal of Pharmaceutics, 2000, 204, 111-116.	5.2	22
43	Methotrexate-poly(lysine) as a selective agent for mutants of chinese hamster ovary cells defective in endocytosis. Journal of Cellular Physiology, 1988, 135, 277-284.	4.1	21
44	Cytosolic delivery of a p16-peptide oligoarginine conjugate for inhibiting proliferation of MCF7 cells. Journal of Controlled Release, 2005, 108, 409-417.	9.9	21
45	Tumor location and drug targeting using a monoclonal antibody (anti-SSEA-1) and antigen-binding fragments. Journal of Surgical Oncology, 1986, 31, 1-12.	1.7	20
46	Comparison of pharmacokinetic parameters of a polypeptide, the Bowman-Birk protease inhibitor (BBI), and its palmitic acid conjugate. Pharmaceutical Research, 1996, 13, 1373-1377.	3.5	20
47	The Transepithelial Transport of a G-CSF-Transferrin Conjugate in Caco-2 Cells and Its Myelopoietic Effect in BDF1 Mice. Pharmaceutical Research, 2004, 21, 278-284.	3.5	20
48	Accumulation of transferrin in Caco-2 cells: A possible mechanism of intestinal transferrin absorption. Journal of Controlled Release, 2007, 122, 393-398.	9.9	19
49	Title is missing!. Journal of Inorganic and Organometallic Polymers, 2000, 10, 93-101.	1.5	16
50	Transferrin-Oligomers as Potential Carriers in Anticancer Drug Delivery. Pharmaceutical Research, 2004, 21, 1985-1992.	3.5	16
51	Receptor-mediated activation of a proinsulin-transferrin fusion protein in hepatoma cells. Journal of Controlled Release, 2011, 155, 386-392.	9.9	16
52	Acid-sensitive dissociation between poly(lysine) and histamine-modified poly(glutamate) as a model for drug-releasing from carriers in endosomes. Biochimica Et Biophysica Acta - General Subjects, 1990, 1034, 122-124.	2.4	14
53	Disulfide and thioether linked cytochrome c-oligoarginine conjugates in HeLa cells. International Journal of Pharmaceutics, 2009, 369, 79-84.	5.2	14
54	Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics. Tissue Barriers, 2016, 4, e1156804.	3.2	13

#	Article	IF	Citations
55	Vesicle-to-cytosol transport of disulfide-linked cargo mediated by an amphipathic cell-penetrating peptide. Journal of Drug Targeting, 2012, 20, 793-800.	4.4	12
56	MAP-mediated nuclear delivery of a cargo protein. Journal of Drug Targeting, 2012, 20, 329-337.	4.4	11
57	Characterization and Oral Delivery of Proinsulin-Transferrin Fusion Protein Expressed Using ExpressTec. International Journal of Molecular Sciences, 2018, 19, 378.	4.1	10
58	Isolation of variants of chinese hamster ovary cells with abnormally low levels of GSH: Decreased ability to cleave endocytosed disulfide bonds. Journal of Cellular Physiology, 1991, 149, 60-65.	4.1	9
59	Molecular and Functional Expression of Multidrug Resistance-Associated Protein-1 in Primary Cultured Rat Alveolar Epithelial Cells. Journal of Pharmaceutical Sciences, 2008, 97, 2340-2349.	3.3	9
60	Biodistribution, activation, and retention of proinsulin-transferrin fusion protein in the liver: Mechanism of liver-targeting as an insulin prodrug. Journal of Controlled Release, 2018, 275, 186-191.	9.9	9
61	Reversible lipidization of somatostatin analogues for the liver targeting. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 615-620.	4.3	8
62	Proinsulinâ€“Transferrin Fusion Protein Exhibits a Prolonged and Selective Effect on the Control of Hepatic Glucose Production in an Experimental Model of Type 1 Diabetes. Molecular Pharmaceutics, 2016, 13, 2641-2646.	4.6	8
63	Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery. Biomaterials, 2017, 117, 24-31.	11.4	8
64	Tyrphostin A8 stimulates a novel trafficking pathway of apically endocytosed transferrin through Rab11-enriched compartments in Caco-2 cells. American Journal of Physiology - Cell Physiology, 2008, 294, C7-C21.	4.6	6
65	Altered endocytosis in a mutant of LM fibroblasts defective in cell-cell fusion. Journal of Cellular Physiology, 1986, 126, 161-166.	4.1	5
66	Antibody-Drug Conjugates: A Historical Review. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 3-7.	0.6	5
67	Stable variant of LM fibroblast defective in fluid-phase but competent in receptor-mediated endocytosis. Journal of Cellular Physiology, 1988, 137, 490-496.	4.1	3
68	Transcellular Transport of Proteinâ€”Polymer Conjugates in Cultured Epithelial Cells. ACS Symposium Series, 1991, , 117-127.	0.5	1
69	Transferrin Receptorâ€“Mediated Transcytosis in Intestinal Epithelial Cells for Gastrointestinal Absorption of Protein Drugs. , 2010, , 31-52.		1